Corcept Therapeutics (CORT)

1 big move explained, newest first · Biotech

  1. Corcept falls 20% as a rival ovarian cancer drug aces its Phase 3 trial

    Corcept had no news of its own. Genmab's Rina-S beat chemotherapy in the same ovarian cancer market as Corcept's new growth drug, Lifyorli.